Precision BioSciences (NASDAQ:DTIL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Precision BioSciences (NASDAQ:DTIL) from a sell rating to a hold rating in a research note released on Saturday morning.

Several other brokerages have also issued reports on DTIL. Weiss Ratings reiterated a “sell (e+)” rating on shares of Precision BioSciences in a research note on Monday, December 22nd. Jefferies Financial Group restated a “buy” rating and set a $19.00 price objective on shares of Precision BioSciences in a research note on Friday. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Precision BioSciences currently has a consensus rating of “Hold” and an average price target of $39.50.

Precision BioSciences Price Performance

NASDAQ DTIL opened at $6.30 on Friday. The firm’s 50 day moving average is $4.22 and its 200-day moving average is $5.00. The company has a quick ratio of 13.32, a current ratio of 13.32 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $155.80 million, a PE ratio of -1.23 and a beta of 1.28. Precision BioSciences has a 12-month low of $3.53 and a 12-month high of $8.82.

Insider Buying and Selling at Precision BioSciences

In other news, insider J. Jefferson Smith sold 10,200 shares of the company’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $4.03, for a total value of $41,106.00. Following the sale, the insider directly owned 110,184 shares of the company’s stock, valued at approximately $444,041.52. This represents a 8.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Michael Amoroso sold 20,559 shares of Precision BioSciences stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $3.84, for a total value of $78,946.56. Following the transaction, the chief executive officer owned 243,392 shares of the company’s stock, valued at $934,625.28. The trade was a 7.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 93,845 shares of company stock worth $376,677 over the last quarter. 4.00% of the stock is currently owned by insiders.

Institutional Trading of Precision BioSciences

Several institutional investors and hedge funds have recently bought and sold shares of DTIL. Empery Asset Management LP acquired a new stake in shares of Precision BioSciences in the fourth quarter valued at approximately $9,130,000. Aberdeen Group plc acquired a new position in shares of Precision BioSciences during the 4th quarter worth approximately $8,897,000. Bleichroeder LP increased its holdings in shares of Precision BioSciences by 54.7% during the 4th quarter. Bleichroeder LP now owns 1,662,500 shares of the company’s stock worth $6,916,000 after acquiring an additional 587,500 shares during the last quarter. Boothbay Fund Management LLC raised its stake in Precision BioSciences by 497.1% in the 4th quarter. Boothbay Fund Management LLC now owns 1,066,050 shares of the company’s stock valued at $4,435,000 after acquiring an additional 887,515 shares during the period. Finally, Lynx1 Capital Management LP raised its stake in Precision BioSciences by 0.6% in the 3rd quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock valued at $5,755,000 after acquiring an additional 6,545 shares during the period. Institutional investors own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.